Evaluation of idiosyncratic drug-induced liver injury based on human in vitro systems

Abstract

Conventional preclinical studies can detect intrinsic hepatotoxicity of candidate compounds but cannot detect idiosyncratic Drug-Induced Liver Injury (iDILI). One of our compounds which has been discontinued by iDILI during clinical trials in the 2000s has forced us to develop a strategy to avoid iDILI. It is mainly based on in vitro covalent binding amounts to classify iDILI compounds, however, includes false positive and negative for the classification. New human in vitro system using T lymphocytes from healthy volunteers to improve the strategy will be discussed in this presentation.